The blood-based test evaluates the presence of tiny clusters of tumour cells. Credit: PublicDomainPictures / Pixabay.

Datar Cancer Genetics has obtained CE Mark for its non-invasive liquid biopsy cancer diagnostic test.

Named TruBlood, the blood-based test serves as a new paradigm to detect, diagnose, and manage cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Datar Cancer Genetics noted that the certification confirms the solution meets European Medical Devices Directive requirements and enables the use of TruBlood in the UK, EU, and other regions, which accept the CE Mark.

The solution evaluates the presence of tiny clusters of tumour cells (C-ETACS) shown to be highly prevalent in the blood of cancer patients and cannot be detected in individuals without cancer.

The test helps people, presenting to their doctors with suspicious growths in the breast, lung, prostate, colon, and brain, possibly suggestive of malignancies, and those who have been recommended to take a biopsy.

TruBlood can also help to diagnose cases where invasive biopsies are unviable for reasons such as proximity of a tumour to a vital organ or blood vessel, or when patients have co-morbidities.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Mid Essex Health Trust medical oncologist Tim Crook said: “TruBlood is an innovative investigation, which facilitates diagnosis of multiple types of cancer from a simple blood sample.

“It uses cutting-edge genomic analysis to identify cancers with a high degree of accuracy. TruBlood represents an exciting advance with numerous future applications in cancer diagnosis.”

Datar Cancer Genetics is planning to market TruBlood as a low-risk, patient-friendly diagnostic assessment for clinical care pathways to prioritise patients with detectable C-ETACs for biopsies.

Meanwhile, the patients who test negative for C-ETACs can be considered for later evaluation, using alternative diagnostic procedures.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact